In addition, in patients with no biochemical significant response (<20% IGF-1 reduction) and without significant tumour shrinkage (<25% tumour volume reduction) during first-generation SRLs monotherapy, PEGV monotherapy is recommended. The gene discussed is IGF1; the disease is neoplasm.